{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:45:55Z","timestamp":1785750355701,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\u201cSapienza\u201d University of Rome, Italy","award":["MA218164304DC6CD"],"award-info":[{"award-number":["MA218164304DC6CD"]}]},{"name":"\u201cSapienza\u201d University of Rome, Italy","award":["RM1221814ED155C3"],"award-info":[{"award-number":["RM1221814ED155C3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11010-025-05331-x","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:28:00Z","timestamp":1750843680000},"page":"5521-5529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elexacaftor\/tezacaftor\/ivacaftor (ETI) therapy modifies the expression of interferon beta and inflammatory genes in the airways of adult patients with cystic fibrosis: a pilot study"],"prefix":"10.1007","volume":"480","author":[{"given":"Camilla","family":"Bitossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"D\u2019Auria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fracella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Radocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Trancassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Petrarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"La Regina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pietropaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Midulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pierangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Scagnolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"5331_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102239","volume":"65","author":"KA Despotes","year":"2022","unstructured":"Despotes KA, Donaldson SH (2022) Current state of CFTR modulators for treatment of cystic fibrosis. Curr Opin Pharmacol 65:102239. https:\/\/doi.org\/10.1016\/j.coph.2022.102239","journal-title":"Curr Opin Pharmacol"},{"issue":"14","key":"5331_CR2","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.3390\/ijms22147606","volume":"22","author":"KH Harwood","year":"2021","unstructured":"Harwood KH, McQuade RM, Jarnicki A, Schneider-Futschik EK (2021) Anti-inflammatory influences of cystic fibrosis transmembrane conductance regulator drugs on lung inflammation in cystic fibrosis. Int J Mol Sci 22(14):7606. https:\/\/doi.org\/10.3390\/ijms22147606","journal-title":"Int J Mol Sci"},{"key":"5331_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.prrv.2023.09.001","volume":"48","author":"N Lieu","year":"2023","unstructured":"Lieu N, Prentice BJ, Field P, Fitzgerald DA (2023) Trials and tribulations of highly effective modulator therapies in cystic fibrosis. Paediatr Respir Rev 48:10\u201319. https:\/\/doi.org\/10.1016\/j.prrv.2023.09.001","journal-title":"Paediatr Respir Rev"},{"issue":"5","key":"5331_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jinf.2020.07.021","volume":"81","author":"C Scagnolari","year":"2020","unstructured":"Scagnolari C, Bitossi C, Frasca F, Viscido A, Brazzini G et al (2020) Differential toll like receptor expression in cystic fibrosis patients\u2019 airways during rhinovirus infection. J Infect 81(5):726\u2013735. https:\/\/doi.org\/10.1016\/j.jinf.2020.07.021","journal-title":"J Infect"},{"issue":"5","key":"5331_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.molcel.2018.07.009","volume":"71","author":"MH Orzalli","year":"2018","unstructured":"Orzalli MH, Smith A, Jurado KA, Iwasaki A, Garlick JA et al (2018) An Antiviral branch of the IL-1 signaling pathway restricts immune-evasive virus replication. Mol Cell 71(5):825-840.e6. https:\/\/doi.org\/10.1016\/j.molcel.2018.07.009","journal-title":"Mol Cell"},{"issue":"7","key":"5331_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.tim.2017.01.001","volume":"25","author":"W Wang","year":"2017","unstructured":"Wang W, Xu L, Su J, Peppelenbosch MP, Pan Q (2017) Transcriptional regulation of antiviral interferon-stimulated genes. Trends Microbiol 25(7):573\u2013584. https:\/\/doi.org\/10.1016\/j.tim.2017.01.001","journal-title":"Trends Microbiol"},{"issue":"7\u20138","key":"5331_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00335-018-9755-6","volume":"29","author":"R Green","year":"2018","unstructured":"Green R, Ireton RC, Gale M Jr (2018) Interferon-stimulated genes: new platforms and computational approaches. Mamm Genome 29(7\u20138):593\u2013602. https:\/\/doi.org\/10.1007\/s00335-018-9755-6","journal-title":"Mamm Genome"},{"key":"5331_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.05.001","volume":"43","author":"S Lukhele","year":"2019","unstructured":"Lukhele S, Boukhaled GM, Brooks DG (2019) Type I interferon signaling, regulation and gene stimulation in chronic virus infection. Semin Immunol 43:101277. https:\/\/doi.org\/10.1016\/j.smim.2019.05.001","journal-title":"Semin Immunol"},{"key":"5331_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3389\/fphar.2020.01219","volume":"11","author":"KB Hisert","year":"2020","unstructured":"Hisert KB, Birkland TP, Schoenfelt KQ, Long ME, Grogan B et al (2020) CFTR modulator therapy enhances peripheral blood monocyte contributions to immune responses in people with cystic fibrosis. Front Pharmacol 11:1219. https:\/\/doi.org\/10.3389\/fphar.2020.01219","journal-title":"Front Pharmacol"},{"issue":"2","key":"5331_CR10","doi-asserted-by":"publisher","first-page":"00318","DOI":"10.1183\/23120541.00318-2019","volume":"6","author":"KB Hisert","year":"2020","unstructured":"Hisert KB, Birkland TP, Schoenfelt KQ, Long ME, Grogan B et al (2020) Ivacaftor decreases monocyte sensitivity to interferon-\u03b3 in people with cystic fibrosis. ERJ Open Res 6(2):00318\u201302019. https:\/\/doi.org\/10.1183\/23120541.00318-2019","journal-title":"ERJ Open Res"},{"issue":"3","key":"5331_CR11","doi-asserted-by":"publisher","first-page":"L432","DOI":"10.1152\/ajplung.00461.2017","volume":"314","author":"R Barnaby","year":"2018","unstructured":"Barnaby R, Koeppen K, Nymon A, Hampton TH, Berwin B et al (2018) Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 314(3):L432\u2013L438. https:\/\/doi.org\/10.1152\/ajplung.00461.2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"5331_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pulmoe.2021.11.008","volume":"30","author":"CS Sousa","year":"2024","unstructured":"Sousa CS, Coelho DB, Amorim P, Viana P, Cruz-Martins N et al (2024) Differences between FEV6, FVC and VC at the diagnosis of obstructive ventilatory defect. Pulmonology 30(2):170\u2013173. https:\/\/doi.org\/10.1016\/j.pulmoe.2021.11.008","journal-title":"Pulmonology"},{"issue":"19","key":"5331_CR13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF et al (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381(19):1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"issue":"2","key":"5331_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M (2022) Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros 21(2):265\u2013271. https:\/\/doi.org\/10.1016\/j.jcf.2021.11.012","journal-title":"J Cyst Fibros"},{"issue":"8","key":"5331_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3390\/jpm11080729","volume":"11","author":"I Sermet-Gaudelus","year":"2021","unstructured":"Sermet-Gaudelus I, Nguyen-Khoa T, Hatton A, Hayes K, Pranke I (2021) Sweat chloride testing and nasal potential difference (NPD) are primary outcome parameters in treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators. J Pers Med 11(8):729. https:\/\/doi.org\/10.3390\/jpm11080729","journal-title":"J Pers Med"},{"issue":"1","key":"5331_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23428","volume":"10","author":"D Westh\u00f6lter","year":"2023","unstructured":"Westh\u00f6lter D, Pipping J, Raspe J, Schmitz M, Sutharsan S et al (2023) Plasma levels of chemokines decrease during elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis. Heliyon 10(1):e23428. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23428","journal-title":"Heliyon"},{"issue":"1","key":"5331_CR17","doi-asserted-by":"publisher","first-page":"2202096","DOI":"10.1183\/13993003.02096-2022","volume":"61","author":"T Dhote","year":"2023","unstructured":"Dhote T, Martin C, Regard L, Pesenti L, Kanaan R et al (2023) Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis. Eur Respir J 61(1):2202096. https:\/\/doi.org\/10.1183\/13993003.02096-2022","journal-title":"Eur Respir J"},{"issue":"4","key":"5331_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","volume":"16","author":"G D\u00f6ring","year":"2000","unstructured":"D\u00f6ring G, Conway SP, Heijerman HG, Hodson ME, H\u00f8iby N et al (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16(4):749\u2013767. https:\/\/doi.org\/10.1034\/j.1399-3003.2000.16d30.x","journal-title":"Eur Respir J"},{"issue":"4","key":"5331_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/INF.0b013e3181fe075e","volume":"30","author":"SA Fritz","year":"2011","unstructured":"Fritz SA, Krauss MJ, Epplin EK, Burnham CA, Garbutt J et al (2011) The natural history of contemporary Staphylococcus aureus nasal colonization in community children. Pediatr Infect Dis J 30(4):349\u2013351. https:\/\/doi.org\/10.1097\/INF.0b013e3181fe075e","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"5331_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00430-024-00808-w","volume":"213","author":"L Bordi","year":"2024","unstructured":"Bordi L, D\u2019Auria A, Frasca F, Mazzotta V, Mazzetti P et al (2024) MPXV infection impairs IFN response but is partially sensitive to IFN-\u03b3 antiviral effect. Med Microbiol Immunol 213(1):25. https:\/\/doi.org\/10.1007\/s00430-024-00808-w","journal-title":"Med Microbiol Immunol"},{"key":"5331_CR21","volume-title":"Sweat testing","author":"H Schmidt","year":"2024","unstructured":"Schmidt H, Sharma G (2024) Sweat testing. StatPearls Publishing, Treasure Island"},{"issue":"167","key":"5331_CR22","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0154-2022","volume":"32","author":"JS Elborn","year":"2023","unstructured":"Elborn JS, Blasi F, Burgel PR, Peckham D (2023) Role of inhaled antibiotics in the era of highly effective CFTR modulators. Eur Respir Rev 32(167):220154. https:\/\/doi.org\/10.1183\/16000617.0154-2022","journal-title":"Eur Respir Rev"},{"issue":"21","key":"5331_CR23","doi-asserted-by":"publisher","first-page":"eadg5128","DOI":"10.1126\/sciadv.adg5128","volume":"9","author":"JL Gillan","year":"2023","unstructured":"Gillan JL, Chokshi M, Hardisty GR, Clohisey Hendry S, Prasca-Chamorro D et al (2023) CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages. Sci Adv 9(21):eadg5128. https:\/\/doi.org\/10.1126\/sciadv.adg5128","journal-title":"Sci Adv"},{"issue":"16","key":"5331_CR24","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.3390\/ijms21165882","volume":"21","author":"A Gramegna","year":"2020","unstructured":"Gramegna A, Contarini M, Aliberti S, Casciaro R, Blasi F et al (2020) From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis. Int J Mol Sci 21(16):5882. https:\/\/doi.org\/10.3390\/ijms21165882","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5331_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304555","volume":"19","author":"HH Jarosz-Griffiths","year":"2024","unstructured":"Jarosz-Griffiths HH, Gillgrass L, Caley LR, Spoletini G, Clifton IJ et al (2024) Anti-inflammatory effects of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis heterozygous for F508del. PLoS ONE 19(5):e0304555. https:\/\/doi.org\/10.1371\/journal.pone.0304555","journal-title":"PLoS ONE"},{"issue":"10212","key":"5331_CR26","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM et al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394(10212):1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet"},{"key":"5331_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100690","volume":"32","author":"S Sutharsan","year":"2023","unstructured":"Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F et al (2023) Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health Eur 32:100690. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100690","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"5331_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","volume":"205","author":"DP Nichols","year":"2022","unstructured":"Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA et al (2022) Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial. Am J Respir Crit Care Med 205(5):529\u2013539. https:\/\/doi.org\/10.1164\/rccm.202108-1986OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"5331_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14(1):36\u201349. https:\/\/doi.org\/10.1038\/nri3581","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5331_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1165\/rcmb.2011-0080OC","volume":"46","author":"D Parker","year":"2012","unstructured":"Parker D, Cohen TS, Alhede M, Harfenist BS, Martin FJ (2012) Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol 46(1):6\u201313. https:\/\/doi.org\/10.1165\/rcmb.2011-0080OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5331_CR31","doi-asserted-by":"publisher","first-page":"1093212","DOI":"10.3389\/fimmu.2023.1093212","volume":"14","author":"L Occhigrossi","year":"2023","unstructured":"Occhigrossi L, Rossin F, Villella VR, Esposito S, Abbate C et al (2023) The STING\/TBK1\/IRF3\/IFN type I pathway is defective in cystic fibrosis. Front Immunol 14:1093212. https:\/\/doi.org\/10.3389\/fimmu.2023.1093212","journal-title":"Front Immunol"},{"issue":"10","key":"5331_CR32","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1128\/IAI.05120-11","volume":"79","author":"SS Chattoraj","year":"2011","unstructured":"Chattoraj SS, Ganesan S, Faris A, Comstock A, Lee WM et al (2011) Pseudomonas aeruginosa suppresses interferon response to rhinovirus infection in cystic fibrosis but not in normal bronchial epithelial cells. Infect Immun 79(10):4131\u20134145. https:\/\/doi.org\/10.1128\/IAI.05120-11","journal-title":"Infect Immun"},{"issue":"11","key":"5331_CR33","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","volume":"209","author":"J Loske","year":"2024","unstructured":"Loske J, V\u00f6ller M, Lukassen S, Stahl M, Th\u00fcrmann L et al (2024) Pharmacological improvement of cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis. Am J Respir Crit Care Med 209(11):1338\u20131350. https:\/\/doi.org\/10.1164\/rccm.202310-1836OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5331_CR34","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3389\/fimmu.2017.01661","volume":"8","author":"I Zanoni","year":"2017","unstructured":"Zanoni I, Granucci F, Broggi A (2017) Interferon (IFN)-\u03bb takes the helm: immunomodulatory roles of Type III IFNs. Front Immunol 8:1661. https:\/\/doi.org\/10.3389\/fimmu.2017.01661","journal-title":"Front Immunol"},{"issue":"9","key":"5331_CR35","doi-asserted-by":"publisher","first-page":"e0162490","DOI":"10.1371\/journal.pone.0162490","volume":"11","author":"JA Nick","year":"2016","unstructured":"Nick JA, Caceres SM, Kret JE, Poch KR, Strand M et al (2016) Extremes of interferon-stimulated gene expression associate with worse outcomes in the acute respiratory distress syndrome. PLoS ONE 11(9):e0162490. https:\/\/doi.org\/10.1371\/journal.pone.0162490","journal-title":"PLoS ONE"},{"key":"5331_CR36","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.05.602290","author":"LG Miller","year":"2024","unstructured":"Miller LG, Chiok K, Mariasoosai C, Mohanty I, Pandit S et al (2024) Extracellular ISG15 triggers ISGylation via a type-I interferon independent non-canonical mechanism to regulate host response during virus infection. bioRxiv. https:\/\/doi.org\/10.1101\/2024.07.05.602290","journal-title":"bioRxiv"},{"issue":"7","key":"5331_CR37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","volume":"16","author":"YC Perng","year":"2018","unstructured":"Perng YC, Lenschow DJ (2018) ISG15 in antiviral immunity and beyond. Nat Rev Microbiol 16(7):423\u2013439. https:\/\/doi.org\/10.1038\/s41579-018-0020-5","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"5331_CR38","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41590-021-01056-3","volume":"22","author":"X Cao","year":"2021","unstructured":"Cao X (2021) ISG15 secretion exacerbates inflammation in SARS-CoV-2 infection. Nat Immunol 22(11):1360\u20131362. https:\/\/doi.org\/10.1038\/s41590-021-01056-3","journal-title":"Nat Immunol"},{"issue":"12","key":"5331_CR39","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1089\/jir.2013.0064","volume":"33","author":"JA Campbell","year":"2013","unstructured":"Campbell JA, Lenschow DJ (2013) Emerging roles for immunomodulatory functions of free ISG15. J Interferon Cytokine Res 33(12):728\u2013738. https:\/\/doi.org\/10.1089\/jir.2013.0064","journal-title":"J Interferon Cytokine Res"},{"issue":"11","key":"5331_CR40","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s12276-022-00872-3","volume":"54","author":"JA Kang","year":"2022","unstructured":"Kang JA, Kim YJ, Jeon YJ (2022) The diverse repertoire of ISG15: more intricate than initially thought. Exp Mol Med 54(11):1779\u20131792. https:\/\/doi.org\/10.1038\/s12276-022-00872-3","journal-title":"Exp Mol Med"},{"key":"5331_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/984708","volume":"2013","author":"H Tanaka","year":"2013","unstructured":"Tanaka H, Imaizumi T (2013) Inflammatory chemokine expression via Toll-like receptor 3 signaling in normal human mesangial cells. Clin Dev Immunol 2013:984708. https:\/\/doi.org\/10.1155\/2013\/984708","journal-title":"Clin Dev Immunol"},{"key":"5331_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jaut.2018.09.007","volume":"96","author":"S Joseph","year":"2019","unstructured":"Joseph S, George NI, Green-Knox B, Treadwell EL, Word B et al (2019) Epigenome-wide association study of peripheral blood mononuclear cells in systemic lupus erythematosus: Identifying DNA methylation signatures associated with interferon-related genes based on ethnicity and SLEDAI. J Autoimmun 96:147\u2013157. https:\/\/doi.org\/10.1016\/j.jaut.2018.09.007","journal-title":"J Autoimmun"},{"issue":"2","key":"5331_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000346415","volume":"37","author":"T Imaizumi","year":"2013","unstructured":"Imaizumi T, Aizawa-Yashiro T, Matsumiya T, Yoshida H, Watanabe S et al (2013) Interaction between interferon-stimulated gene 56 and melanoma differentiation-associated gene 5 in Toll-like receptor 3 signaling in normal human mesangial cells. Am J Nephrol 37(2):118\u2013125. https:\/\/doi.org\/10.1159\/000346415","journal-title":"Am J Nephrol"},{"key":"5331_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neures.2014.03.001","volume":"84","author":"T Imaizumi","year":"2014","unstructured":"Imaizumi T, Numata A, Yano C, Yoshida H, Meng P et al (2014) ISG54 and ISG56 are induced by TLR3 signaling in U373MG human astrocytoma cells: possible involvement in CXCL10 expression. Neurosci Res 84:34\u201342. https:\/\/doi.org\/10.1016\/j.neures.2014.03.001","journal-title":"Neurosci Res"},{"issue":"19","key":"5331_CR45","doi-asserted-by":"publisher","first-page":"7945","DOI":"10.1073\/pnas.0900818106","volume":"106","author":"Y Li","year":"2009","unstructured":"Li Y, Li C, Xue P, Zhong B, Mao AP et al (2009) ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response. Proc Natl Acad Sci U S A 106(19):7945\u20137950. https:\/\/doi.org\/10.1073\/pnas.0900818106","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5331_CR46","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ppul.26261","volume":"58","author":"S Sheikh","year":"2023","unstructured":"Sheikh S, Britt RD Jr, Ryan-Wenger NA, Khan AQ, Lewis BW et al (2023) Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis. Pediatr Pulmonol 58(3):825\u2013833. https:\/\/doi.org\/10.1002\/ppul.26261","journal-title":"Pediatr Pulmonol"},{"issue":"13","key":"5331_CR47","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2174\/1389450117666151209120516","volume":"17","author":"X Guan","year":"2016","unstructured":"Guan X, Hou Y, Sun F, Yang Z, Li C (2016) Dysregulated chemokine signaling in cystic fibrosis lung disease: a potential therapeutic target. Curr Drug Targets 17(13):1535\u20131544. https:\/\/doi.org\/10.2174\/1389450117666151209120516","journal-title":"Curr Drug Targets"},{"issue":"5","key":"5331_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037689","volume":"7","author":"A Tang","year":"2012","unstructured":"Tang A, Sharma A, Jen R, Hirschfeld AF, Chilvers MA et al (2012) Inflammasome-mediated IL-1\u03b2 production in humans with cystic fibrosis. PLoS ONE 7(5):e37689. https:\/\/doi.org\/10.1371\/journal.pone.0037689","journal-title":"PLoS ONE"},{"issue":"12","key":"5331_CR49","doi-asserted-by":"publisher","first-page":"e114884","DOI":"10.1371\/journal.pone.0114884","volume":"9","author":"J Palomo","year":"2014","unstructured":"Palomo J, Marchiol T, Piotet J, Fauconnier L, Robinet M et al (2014) Role of IL-1\u03b2 in experimental cystic fibrosis upon P. aeruginosa infection. PLoS ONE 9(12):e114884. https:\/\/doi.org\/10.1371\/journal.pone.0114884","journal-title":"PLoS ONE"},{"issue":"10","key":"5331_CR50","doi-asserted-by":"publisher","first-page":"5492","DOI":"10.3390\/ijms25105492","volume":"25","author":"CJ Cheetham","year":"2024","unstructured":"Cheetham CJ, McKelvey MC, McAuley DF, Taggart CC (2024) Neutrophil-derived proteases in lung inflammation: old players and new prospects. Int J Mol Sci 25(10):5492. https:\/\/doi.org\/10.3390\/ijms25105492","journal-title":"Int J Mol Sci"},{"issue":"127","key":"5331_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1183\/09059180.00008412","volume":"22","author":"N Derichs","year":"2013","unstructured":"Derichs N (2013) Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 22(127):58\u201365. https:\/\/doi.org\/10.1183\/09059180.00008412","journal-title":"Eur Respir Rev"},{"issue":"1","key":"5331_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00408-025-00806-6","volume":"203","author":"MS Garc\u00eda","year":"2025","unstructured":"Garc\u00eda MS, Madrid-Carbajal CJ, Pel\u00e1ez A, Moreno RMG, Alonso EF et al (2025) The role of triple CFTR modulator therapy in reducing systemic inflammation in cystic fibrosis. Lung 203(1):55\u201356. https:\/\/doi.org\/10.1007\/s00408-025-00806-6","journal-title":"Lung"},{"key":"5331_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cca.2020.05.015","volume":"508","author":"Z Bene","year":"2020","unstructured":"Bene Z, Fejes Z, Macek M Jr, Amaral MD, Balogh I et al (2020) Laboratory biomarkers for lung disease severity and progression in cystic fibrosis. Clin Chim Acta 508:277\u2013286. https:\/\/doi.org\/10.1016\/j.cca.2020.05.015","journal-title":"Clin Chim Acta"},{"issue":"8","key":"5331_CR54","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1164\/rccm.200609-1354OC","volume":"175","author":"N Mayer-Hamblett","year":"2007","unstructured":"Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW et al (2007) Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 175(8):822\u2013828. https:\/\/doi.org\/10.1164\/rccm.200609-1354OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"5331_CR55","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jcf.2015.03.007","volume":"14","author":"JF Chmiel","year":"2015","unstructured":"Chmiel JF, Konstan MW, Accurso FJ, Lymp J, Mayer-Hamblett N et al (2015) Assessment of induced sputum in cystic fibrosis study group. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: implications for clinical trials in cystic fibrosis. J Cyst Fibros 14(6):720\u2013726.\u00a0https:\/\/doi.org\/10.1016\/j.jcf.2015.03.007","journal-title":"J Cyst Fibros"},{"key":"5331_CR56","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.25.24310916","author":"R Maher","year":"2024","unstructured":"Maher R, Cytlak-Chaudhuri U, Aleem S, Barry PJ, Brice D et al (2024) The effect of highly effective modulator therapy on systemic inflammation in cystic fibrosis. medRxiv. https:\/\/doi.org\/10.1101\/2024.07.25.24310916","journal-title":"medRxiv"},{"issue":"1","key":"5331_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TW Lee","year":"2003","unstructured":"Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM (2003) Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2(1):29\u201334. https:\/\/doi.org\/10.1016\/S1569-1993(02)00141-8","journal-title":"J Cyst Fibros"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05331-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05331-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05331-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:47:57Z","timestamp":1760168877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05331-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5331"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05331-x","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests, as defined by Springer, or other interests that might be perceived as influencing the results and\/or discussion reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the ethics committee of the Policlinico Umberto I Hospital (Rif. 5223), Sapienza University of Rome, and informed consent was obtained from patients suffering from CF.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}